There is one clinical trial.
IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments could result in earlier detection of recurrent disease and identify more patients eligible for curative treatment.
QoL/Utility weights for the quality-adjusted life years parameter will be QLU-C10D based on EORTC QLQ-C30.. Inclusion Criteria: - Colon or rectal cancer, tumor stage III (pT1-4N1-2,cM0) or stage II high-risk (pT4N0,cM0 and pT3N0, cM0 with risk factors) - Have received curative intend resection and be candidates for adjuvant chemotherapy Exclusion Criteria: - Not treated with adjuvant chemotherapy - Synchronous colorectal and non-colorectal cancer diagnosed per-operative (except skin cancer other than melanoma) - Other cancers (excluding colorectal cancer or skin cancer other than melanoma) within 3 years from screening - Patients who are unlikely to comply with the protocol (e.g. --- C10D ---
Description: Fraction of patients with relapse receiving intended curative resection or local treatment aiming at complete tumor destruction as defined at the relevant MDT conference.
Measure: FCI Time: 5 yearsDescription: Overall survival at 3 years
Measure: 3yr-OS Time: 3 yearsDescription: Overall survival at 5 years
Measure: 5yr-OS Time: 5 yearsDescription: Time to clinical recurrence
Measure: TTCR Time: 3 yearsDescription: Time to molecular recurrence
Measure: TTMR Time: 2 yearsDescription: Quality of Life by use of EORTC QLQ-C30, version 3.0. The QoL outcome measure is differences in QLQ-C30 score at 12, 24 and 36 months between the experimental and control arm.
Measure: QoL Time: 3 yearsDescription: Fear of Cancer Recurrence Inventory. The FCRI outcome measure is differences in FCRI at 12, 24 and 36 months between the experimental and control arm.
Measure: FCRI Time: 3 yearsDescription: Impact of Events Scale Cancer. The IES-C outcome measure is differences in IES-C at 12, 24 and 36 months between the experimental and control arm.
Measure: IES-C Time: 3 yearsDescription: Cost-effectiveness. QoL/Utility weights for the quality-adjusted life years parameter will be QLU-C10D based on EORTC QLQ-C30.
Measure: CE Time: 5 years